Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

Slides:

Advertisements

Similar presentations

The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure Internal Medicine/Pediatrics.

Advertisements

JNC 8 Guidelines….

Canadian Diabetes Association Clinical Practice Guidelines Weight Management in Diabetes Chapter 17 Sean Wharton, Arya M. Sharma, David C.W. Lau.

Canadian Diabetes Association Clinical Practice Guidelines Chronic Kidney Disease in Diabetes Chapter 29 Phil McFarlane, Richard E. Gilbert, Lori MacCallum,

Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.

ASCOT TRIAL Abbas Zaidi 20/09/05. Hypertension is one of the most prevalent risk factors for cardiovascular disease, affecting as many as 800 million.

Assessment and Management of Patients With Hypertension.

Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Hypertension Chapter 25 Richard E. Gilbert, Doreen Rabi, Pierre LaRochelle, Lawrence.

Heart Failure: Living with a Hurting Heart. Congestive Heart Failure Heart (or cardiac) failure is the state in which the heart is unable to pump blood.

Canadian Diabetes Association Clinical Practice Guidelines Screening for the Presence of Coronary Artery Disease Chapter 23 Paul Poirier, Robert Dufour,

Canadian Diabetes Association 2013 Clinical Practice Guidelines Targets for Glycemic Control Chapter 8 S. Ali Imran, Rémi Rabasa-Lhoret, Stuart Ross.

Canadian Diabetes Association Clinical Practice Guidelines Vascular Protection in People with Diabetes Chapter 22 James A. Stone, David Fitchett, Steven.

Canadian Diabetes Association Clinical Practice Guidelines Erectile Dysfunction Chapter 33 Gerald Brock, William Harper.

Canadian Diabetes Association Clinical Practice Guidelines Management of Stroke in Diabetes Chapter 27 Michael Sharma, Gord Gubitz.

Reducing the Risk of Developing Diabetes Chapter 5 Thomas Ransom, Ronald Goldenberg, Amanda Mikalachki, Ally PH Prebtani, Zubin Punthakee Canadian Diabetes.

Pharmacologic Treatment of Chronic Systolic Heart Failure John N. Hamaty D.O. FACC, FACOI.

Drugs for Hypertension

Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Investigations: Urine examination. Urine examination. Serum K. Serum K. Serum creatinine. Serum creatinine. Blood Sugar. Blood Sugar. Hb. Hb.

1 EFFECT STUDY 2 EFFECT STUDY  Set national cardiac care benchmarks for hospitals to work towards 

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.

S. HUNT Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.

10 Points to Remember on An Effective Approach to High Blood Pressure ControlAn Effective Approach to High Blood Pressure Control Summary Prepared by Debabrata.

Entresto® (sacubitril & valsartan)

Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy

Treatment and Risk in Heart Failure: Gaps in Evidence or Quality? Pamela N. Peterson, MD MSPH; John S. Rumsfeld, MD PhD; Li Liang PhD; Adrian F. Hernandez,

Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.

PHARMACOTHERAPY OF HYPERTENSION Based on New Guidelines Fariborz Nikaeen; MD Interventional cardiologist 2 november 2015.

CURRENT APPROACH TO THE TREATMENT OF CONGESTIVE HEART FAILURE.

Internal Medicine Workshop Series Laos September /October 2009

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Dr.AZDAKI (cardiologist).   Initial monotherapy is successful in many patients with mild primary hypertension (formerly called "essential" hypertension).

CR-1 Candesartan in HF Benefit/Risk James B. Young, MD Cleveland Clinic Foundation.

MACROVASCULAR COMPLICATIONS, DYSLIPIDEMIA and HYPERTENSION 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.

Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,

Treatment of Hypertension in Adults With Diabetes DR AMAL HARFOUSH.

PHARMACOLOGIC THERAPY  Standard First-Line Therapies Angiotensin-Converting Enzyme Inhibitors (ACEI) β Blockers Diuretics Digoxin  Second line Therapies.

Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,

Date of download: 6/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Quality of Care of and Outcomes for African Americans.

Date of download: 6/23/2016 From: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Management of progression of CKD 순천향 대학병원 신장내과 강혜란.

Copyright © 2015 by the American Osteopathic Association.

Angiotensin converting enzyme inhibitors / angiotensin receptor blockers and contrast induced nephropathy in patients receiving cardiac catheterization:

Systemic Implementation Strategies to Improve Hypertension: The Kaiser Permanente Southern California Experience John J. Sim, MD, Joel Handler, MD, Steven.

JNC VIII Hypertension.

Hypertension JNC VIII Guidelines.

Baseline characteristics and effectiveness results

Copyright © 2006 American Medical Association. All rights reserved.

Progress and Promise in RAAS Blockade

Step Care Therapy for Hypertension in Diabetic Patients

Antihyperglycemic therapy in type 2 diabetes: general recommendations

The following slides are based on a report from a presentation at the Late Breaking Clinical Trials Session of the American Heart Association Scientific.

RCHC’s Cardiovascular Health Initiative

Treatment of Diabetes in People with Heart Failure

Fig. 2. Evidence-based medication prescriptions

Nat. Rev. Cardiol. doi: /nrcardio

Table of Contents Why Do We Treat Hypertension? Recommendation 5

The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study was a double-blind, randomized, placebo-controlled study.

Chapter 32 Assessment and Management of Patients With Hypertension

Treatment Algorithm for Guideline-Directed Medical Therapy Including Novel Therapies (2,9) Green diamonds indicate Class I guideline recommendations, while.

Internal Medicine Workshop Series Laos September /October 2009

Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Combination angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) reduced risk for renal end point versus ACEI or ARB. Effect.

Presentation transcript:

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Treat heart failure in patients with diabetes the SAME as you would a patient without diabetes METFORMIN recommended if eGFR >30 mL/min If eGFR <60 mL/min, use RAAS blockade carefully Do NOT use thiazolidinediones 2013 Diabetes in Heart Failure Checklist

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Diabetic cardiomyopathy 2 to 4-fold increase incidence of heart failure in DM Asymptomatic abnormalities of ventricular systolic and diastolic function, independent of ischemic heart disease or systemic hypertension Independent risk factors for CHF – Elevated A1C – Microalbuminuria Diabetes → Increased Risk of Heart Failure Independent of Ischemia

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Use the same heart failure therapies in diabetes as you would in non-diabetes based on the Canadian Cardiovascular Society (CCS) Recommendations (

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Beta-blocker for systolic heart failure if indicated Same target drug dose as indicated by CCS If eGFR <60 mL/min – Starting dose of ACEi/ARB should be halved with gradual up-titration – Monitor electrolytes, creatinine, blood pressure, weight within 7-10 days of starting Use Same Treatments as in Non-diabetes …

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association ACEi = Angiotensin-Converting Enzyme inhibitor; CHF = Chronic Heart Failure; MI = Myocardial Infarction; SU = Sulfonylurea Tayside, Scotland (population 400,000) n=422 with CHF and diabetes Antihyperglycemic therapy: – Metformin alone n=68 – SU alone n=217 – Combination n=137 Cumulative mortality Time (days) Sulfonylurea monotherapy Metformin monotherapy + combination Evans JM, et al. Am J Cardiol 2010;106: Metformin Use in Heart Failure Patients

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Veterans Affairs 6,185 with CHF & DM Oral antihyperglycemic: -With metformin (n=1,561) -Without metformin Statistically adjusted for co-variables Death:0.76 ( ) p < 0.01 CHF hospitalization:0.93 ( ) p = 0.56 Total hospitalization:0.94 ( ) p = 0.35 Survival estimates Time (days) Metformin No metformin p = 0.01 Aguilar D, et al. Circ Heart Fail 2011;4:53-8. Metformin Use in Heart Failure Patients

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association Use metformin in heart failure patients when eGFR >30 mL/min

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 1.Individuals with diabetes and heart failure should receive the same heart failure therapies as those identified in the evidence- based Canadian Cardiovascular Society heart failure recommendations ( [Grade D, Consensus] Recommendation 1

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 2.In people with diabetes and heart failure and an eGFR <60 mL/min, or if combined RAAS blockade is employed: – Starting doses of ACE inhibitors or angiotensin receptor II antagonists (ARBs) should be halved [Grade D, Consensus]. – Serum electrolytes and creatinine, blood pressure and body weight, as well as heart failure symptoms and signs, should be monitored within 7-10 days of any initiation or titration of therapy [Grade D, Consensus] Recommendation 2

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association – Dose-up titration should be more gradual (with monitoring of blood pressure, serum potassium and creatinine) [Grade D, Consensus]. – The target drug doses should be the same as those identified in the evidence-based Canadian Cardiovascular Society recommendations on heart failure ( if well tolerated [Grade D, Consensus] Recommendation 2 (continued)

guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association 3.Beta blockers should be prescribed when indicated for systolic heart failure, as they provide similar benefits in people with diabetes compared with people without diabetes [Grade B, Level 2] Recommendation 3

CDA Clinical Practice Guidelines – for professionals BANTING ( ) – for patients